• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

现代局部晚期非小细胞肺癌的管理:一项关于诊断、治疗和多学科方法的意大利全国性调查。

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.

机构信息

Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.

Department of Advanced Radiation Oncology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy.

出版信息

PLoS One. 2019 Nov 13;14(11):e0224027. doi: 10.1371/journal.pone.0224027. eCollection 2019.

DOI:10.1371/journal.pone.0224027
PMID:31721773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6853329/
Abstract

Concurrent chemotherapy and radiotherapy (cCRT) is considered the standard treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Unfortunately, management is still heterogeneous across different specialists. A multidisciplinary approach is needed in this setting due to recent, promising results obtained by consolidative immunotherapy. The aim of this survey is to assess current LA-NSCLC management in Italy. From January to April 2018, a 15-question survey focusing on diagnostic/therapeutic LA-NSCLC management was sent to 1,478 e-mail addresses that belonged to pneumologists, thoracic surgeons, and radiation and medical oncologists. 421 answers were analyzed: 176 radiation oncologists, 86 medical oncologists, 92 pneumologists, 64 thoracic surgeons and 3 other specialists. More than a half of the respondents had been practicing for >10 years after completing residency training. Some discrepancies were observed in clinical LA-NSCLC management: the lack of a regularly planned multidisciplinary tumor board, the use of upfront surgery in multistation stage IIIA, and territorial diffusion of cCRT in unresectable LA-NSCLC. Our analysis demonstrated good compliance with international guidelines in the diagnostic workup of LA-NSCLC. We observed a relationship between high clinical experience and good clinical practice. A multidisciplinary approach is mandatory for managing LA-NSCLC.

摘要

同期放化疗(cCRT)被认为是局部晚期非小细胞肺癌(LA-NSCLC)的标准治疗方法。遗憾的是,不同专业医生的治疗方案仍存在差异。由于巩固性免疫疗法最近取得了令人鼓舞的结果,因此在此背景下需要采用多学科方法。本次调查旨在评估意大利目前对 LA-NSCLC 的治疗管理情况。2018 年 1 月至 4 月,我们向 1478 名电子邮件地址属于肺科医生、胸外科医生、放射肿瘤学家和肿瘤内科医生的人员发送了一份聚焦于 LA-NSCLC 诊断/治疗管理的 15 个问题的调查。共收到 421 份回复,其中包括 176 名放射肿瘤学家、86 名肿瘤内科医生、92 名肺科医生、64 名胸外科医生和 3 名其他专家。超过一半的受访者在完成住院医师培训后已经行医超过 10 年。在 LA-NSCLC 的临床管理方面观察到一些差异:缺乏定期计划的多学科肿瘤委员会,在多站 IIIA 期采用初始手术,以及不可切除的 LA-NSCLC 中 cCRT 的地域扩散。我们的分析表明,在 LA-NSCLC 的诊断工作中,与国际指南有较好的一致性。我们观察到高临床经验与良好临床实践之间存在关系。多学科方法是治疗 LA-NSCLC 的必要手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/7984d943df15/pone.0224027.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/49bacfd1cfcc/pone.0224027.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/4be3abc0d020/pone.0224027.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/bc6ba2eec36e/pone.0224027.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/01c13684a1d3/pone.0224027.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/7984d943df15/pone.0224027.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/49bacfd1cfcc/pone.0224027.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/4be3abc0d020/pone.0224027.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/bc6ba2eec36e/pone.0224027.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/01c13684a1d3/pone.0224027.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a695/6853329/7984d943df15/pone.0224027.g005.jpg

相似文献

1
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.现代局部晚期非小细胞肺癌的管理:一项关于诊断、治疗和多学科方法的意大利全国性调查。
PLoS One. 2019 Nov 13;14(11):e0224027. doi: 10.1371/journal.pone.0224027. eCollection 2019.
2
Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.不可切除的非小细胞肺癌治疗临床实践指南。1997年5月16日由美国临床肿瘤学会采用。
J Clin Oncol. 1997 Aug;15(8):2996-3018. doi: 10.1200/JCO.1997.15.8.2996.
3
Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States.III 期非小细胞肺癌的治疗决策因素:一项针对美国肿瘤学家的网络调查结果。
JCO Oncol Pract. 2020 Oct;16(10):e1232-e1242. doi: 10.1200/JOP.19.00781. Epub 2020 Jun 18.
4
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.在非小细胞肺癌的诊断和治疗决策中导航:多学科团队方法的专家评论。
Oncologist. 2021 Feb;26(2):e306-e315. doi: 10.1002/onco.13586. Epub 2020 Nov 21.
5
Recent trends in the treatment of unresectable stage III non-small-cell lung cancer.不可切除的 III 期非小细胞肺癌的治疗新趋势
Respir Investig. 2019 Jul;57(4):330-336. doi: 10.1016/j.resinv.2019.03.004. Epub 2019 Apr 15.
6
Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.II期非小细胞肺癌(NSCLC)患者的非手术治疗方法:对加拿大医学肿瘤学家和放射肿瘤学家的一项调查
Lung Cancer. 2016 Apr;94:74-80. doi: 10.1016/j.lungcan.2016.02.002. Epub 2016 Feb 3.
7
Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.III 期非小细胞肺癌:英国全国实践调查。
Clin Oncol (R Coll Radiol). 2020 Aug;32(8):527-536. doi: 10.1016/j.clon.2020.03.001. Epub 2020 Mar 23.
8
Combined modality therapy of early stage nonsmall cell lung cancer.早期非小细胞肺癌的综合治疗
Respir Care Clin N Am. 2003 Jun;9(2):191-205. doi: 10.1016/s1078-5337(02)00088-6.
9
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.美国非小细胞肺癌的实践模式调查
Cancer. 2000 Mar 15;88(6):1336-46. doi: 10.1002/(sici)1097-0142(20000315)88:6<1336::aid-cncr9>3.0.co;2-m.
10
Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer.肺科医生和胸外科医生对非小细胞肺癌治疗方法的看法。
Chest. 2000 Jul;118(1):129-37. doi: 10.1378/chest.118.1.129.

引用本文的文献

1
Fast-Track Diagnostic Pathway for Lung Cancer Detection: Single-Center Experience.肺癌检测的快速诊断途径:单中心经验
J Clin Med. 2025 Apr 23;14(9):2915. doi: 10.3390/jcm14092915.
2
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer.虚拟多学科肿瘤委员会:以肺癌为重点的叙述性综述
Pulm Ther. 2021 Dec;7(2):295-308. doi: 10.1007/s41030-021-00163-8. Epub 2021 Jun 4.
3
Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

本文引用的文献

1
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
2
Multidisciplinary team working contributes to lung cancer survival.多学科团队协作有助于提高肺癌患者的生存率。
BMJ. 2018 Jun 20;361:k1904. doi: 10.1136/bmj.k1904.
3
Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach.采用多学科团队方法治疗的肺癌患者的生存结果。
序贯化疗低分割放疗与同期标准放化疗治疗局部晚期非小细胞肺癌:意大利放射肿瘤学会(AIRO)的 GRADE 推荐。
Radiol Med. 2021 Aug;126(8):1117-1128. doi: 10.1007/s11547-021-01362-8. Epub 2021 May 5.
Clin Lung Cancer. 2018 Jul;19(4):346-351. doi: 10.1016/j.cllc.2018.01.006. Epub 2018 Feb 1.
4
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
5
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌(NSCLC):ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222.
6
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer.局部晚期非小细胞肺癌的放射(化学)治疗
Eur Respir Rev. 2016 Mar;25(139):65-70. doi: 10.1183/16000617.0053-2015.
7
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究(ESPATUE)
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
8
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.诱导化疗联合放化疗治疗 IIIA/N2 期非小细胞肺癌:一项 3 期随机试验。
Lancet. 2015 Sep 12;386(9998):1049-56. doi: 10.1016/S0140-6736(15)60294-X. Epub 2015 Aug 11.
9
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.标准剂量与高剂量适形放疗联合并巩固使用卡铂加紫杉醇,联合或不联合西妥昔单抗治疗IIIA期或IIIB期非小细胞肺癌患者(RTOG 0617):一项随机、二乘二析因3期研究。
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
10
Multidisciplinary lung cancer meetings: improving the practice of radiation oncology and facing future challenges.多学科肺癌会议:改善放射肿瘤学实践并应对未来挑战。
Respirology. 2015 Feb;20(2):192-8. doi: 10.1111/resp.12459. Epub 2015 Jan 12.